Patent application number | Description | Published |
20090163411 | LONG ACTING VEGF INHIBITORS AND METHODS OF USE - Disclosed are polymer sFlt-1 conjugates, variants of sFlt-1, compositions comprising such conjugates and variants, including cysteine variants of sFlt-1. Also disclosed is the use of such conjugates, variants and compositions in methods to inhibit the activity of VEGF, to inhibit angiogenesis, and to treat or reduce at least one symptom of diseases and conditions in which it is desirable to inhibit VEGF activity and/or angiogenesis. | 06-25-2009 |
20090208453 | High pressure treatment of aggregated interferons - High pressure to treat aggregated interferons, particularly recombinant human interferon-β, to reduce the aggregate content of interferon material. Highly pure, soluble monomeric recombinant interferon-β is prepared in representative embodiments. Multiple strategies may be used in combination that make nonglycosylated IFN-β more amenable to high pressure treatment. It has been found that refolding yields of high pressure treatment can be significantly improved by use of a combination of strategies, including, or example a pre-treatment of the IFN-β that involves solubilizing and then precipitating the protein. This pre-treatment is particularly effective with respect to recombinant IFN-β inclusion bodies recovered from host cells such as | 08-20-2009 |
20090249503 | ENZYME CONJUGATES FOR USE AS DETOXIFYING AGENTS - Disclosed are detoxifying enzyme conjugates, including conjugates of variants of such detoxifying enzymes. The detoxifying enzymes are preferably chlolinesterases, and more preferably, butyrylcholinesterase. Also disclosed are methods of making and using such conjugates. | 10-01-2009 |
20090269804 | Methods for refolding proteins containing free cysteine residues - The present invention relates to novel methods for making and refolding insoluble or aggregated proteins having free cysteines in which a host cell expressing the protein is exposed to a cysteine blocking agent. The soluble, refolded proteins produced by the novel methods can then be modified to increase their effectiveness. Such modifications include attaching a PEG moiety to form PEGylated proteins. | 10-29-2009 |
20100048872 | METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES - The present invention relates to novel methods of making soluble proteins having free cysteines in which a host cell is exposed to a cysteine blocking agent. The soluble proteins produced by the methods can then be modified to increase their effectiveness. Such modifications include attaching a PEG moiety to form pegylated proteins. | 02-25-2010 |
20100112660 | Method for Derivatization of Proteins Using Hydrostatic Pressure - The present invention provides an effective method for derivatization of proteins using hydrostatic pressure to reversibly perturb the native conformation of a protein such that a normally buried functional group on the protein, such as an amino acid residue, or a ligand or cofactor associated with the protein, is exposed and available for derivatization by a polymer molecule or a cytotoxic agent. The methods described herein do not require use of chaotropes, changes in pH, changes in temperature, or genetic modification of the native primary sequence of the protein and are applicable to substantially all proteins. | 05-06-2010 |
20100121032 | LONG ACTING PROTEINS AND PEPTIDES AND METHODS OF MAKING AND USING THE SAME - Disclosed is a method for refolding a protein or peptide that does not contain essential disulfides and that contains at least one free cysteine residue. Also disclosed are polymer IFN-γ conjugates that have been created by the chemical coupling of polymers such as polyethylene glycol moieties to IFN-γ, particularly via a free cysteine in the protein. Also disclosed are analogs of bioactive peptides that may be used to create longer acting versions of the peptides, including analogs of glucagon, glucagon-like peptide-1 (GLP-1), GLP-2, Gastric inhibitory peptide (GIP), PYY, exendin, ghrelin, gastrin, amylin, and oxyntomodulin. | 05-13-2010 |
20110189124 | METHODS FOR REFOLDING PROTEINS CONTAINING FREE CYSTEINE RESIDUES - The present invention relates to novel methods for making and refolding insoluble or aggregated proteins having free cysteines in which a host cell expressing the protein is exposed to a cysteine blocking agent. The soluble, refolded proteins produced by the novel methods can then be modified to increase their effectiveness. Such modifications include attaching a PEG moiety to form PEGylated proteins. | 08-04-2011 |
20120064573 | METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES - The present invention relates to novel methods of making soluble proteins having free cysteines in which a host cell is exposed to a cysteine blocking agent. The soluble proteins produced by the methods can then be modified to increase their effectiveness. Such modifications include attaching a PEG moiety to form pegylated proteins. | 03-15-2012 |
20130058895 | High Pressure Treatment of Aggregated Interferons - Methods are provided using high pressure to treat aggregated interferons, to reduce the aggregate content of interferon material. In particular, recombinant human interferon-β may be so treated. Multiple strategies may be used in combination to make nonglycosylated IFN-β more amenable to high pressure treatment. When coupled with purification techniques, these strategies singly or in combination provide a low aggregate or substantially aggregate free, biologically active solution. In certain aspects, pharmaceutical compositions containing nonglycosylated interferon having less than about 5 weight percent of protein aggregation are provided. | 03-07-2013 |
20130137645 | MODIFIED PEPTIDES AND PROTEINS - Provided are compounds and methods of making compounds containing two or three groups derived from a peptide, such as enfuvirtide or exenatide, covalently bound to a linker. The compounds may contain polyethylene glycol groups to enhance solubility and pharmacokinetic properties. The compounds are useful for the treatment of diseases or conditions subject to treatment with the parent peptide, such as HIV and AIDS in the case of enfuvirtide, or diabetes in the case of exenatide. | 05-30-2013 |
20130217629 | METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES - The present invention relates to novel methods of making soluble proteins having free cysteines in which a host cell is exposed to a cysteine blocking agent. The soluble proteins produced by the methods can then be modified to increase their effectiveness. Such modifications include attaching a PEG moiety to form pegylated proteins. | 08-22-2013 |
20140309168 | MODIFIED PEPTIDES AND PROTEINS - Provided are compounds and methods of making compounds containing two or three groups derived from a peptide, such as enfuvirtide or exenatide, covalently bound to a linker. The compounds may contain polyethylene glycol groups to enhance solubility and pharmacokinetic properties. The compounds are useful for the treatment of diseases or conditions subject to treatment with the parent peptide, such as HIV and AIDS in the case of enfuvirtide, or diabetes in the case of exenatide. | 10-16-2014 |
20150023918 | LONG ACTING PROTEINS AND PEPTIDES AND METHODS OF MAKING AND USING THE SAME - Disclosed is a method for refolding a protein or peptide that does not contain essential disulfides and that contains at least one free cysteine residue. Also disclosed are polymer IFN-γ conjugates that have been created by the chemical coupling of polymers such as polyethylene glycol moieties to IFN-γ, particularly via a free cysteine in the protein. Also disclosed are analogs of bioactive peptides that may be used to create longer acting versions of the peptides, including analogs of glucagon, glucagon-like peptide-1 (GLP-1), GLP-2, Gastric inhibitory peptide (GIP), PYY, exendin, ghrelin, gastrin, amylin, and oxyntomodulin. | 01-22-2015 |